Viscidi R - Search Results

1

Predominance of defective proviral sequences in an HIV + long-term non-progressor.

Schwartz DH, Viscidi R, Laeyendecker O, Song H, Ray SC, Michael N. Schwartz DH, et al. Among authors: viscidi r. Immunol Lett. 1996 Jun;51(1-2):3-6. doi: 10.1016/0165-2478(96)02547-3. Immunol Lett. 1996. PMID: 8811337 Free article.

2

Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression.

Strunnikova N, Ray SC, Livingston RA, Rubalcaba E, Viscidi RP. Strunnikova N, et al. Among authors: viscidi rp. J Virol. 1995 Dec;69(12):7548-58. doi: 10.1128/JVI.69.12.7548-7558.1995. J Virol. 1995. PMID: 7494261 Free PMC article.

3

Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.

Lambert JS, Viscidi R, Walker MC, Clayman B, Winget M, Wolff M, Schwartz DH. Lambert JS, et al. Among authors: viscidi r. Clin Diagn Lab Immunol. 1997 May;4(3):302-8. doi: 10.1128/cdli.4.3.302-308.1997. Clin Diagn Lab Immunol. 1997. PMID: 9144368 Free PMC article. Clinical Trial.

4

Evolution of human immunodeficiency virus type 1 in relation to disease progression in children.

Strunnikova N, Ray SC, Lancioni C, Nguyen M, Viscidi RP. Strunnikova N, et al. Among authors: viscidi rp. J Hum Virol. 1998 Mar-Apr;1(3):224-39. J Hum Virol. 1998. PMID: 10195246

5

Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.

Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G. Viscidi R, et al. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1251-6. doi: 10.1089/aid.1990.6.1251. AIDS Res Hum Retroviruses. 1990. PMID: 1706607 Clinical Trial.

6

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

Viscidi RP, Mayur K, Lederman HM, Frankel AD. Viscidi RP, et al. Science. 1989 Dec 22;246(4937):1606-8. doi: 10.1126/science.2556795. Science. 1989. PMID: 2556795

7

[No title available]

[No authors listed] [No authors listed] PMID: 8914767

8

Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China.

Yu XF, Chen J, Shao Y, Beyrer C, Liu B, Wang Z, Liu W, Yang J, Liang S, Viscidi RP, Gu J, Gurri-Glass G, Lai S. Yu XF, et al. Among authors: viscidi rp. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):180-8. doi: 10.1097/00126334-199910010-00011. J Acquir Immune Defic Syndr. 1999. PMID: 10843533

9

Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.

Silverberg MJ, Schneider MF, Silver B, Anastos KM, Burk RD, Minkoff H, Palefsky J, Levine AM, Viscidi RP. Silverberg MJ, et al. Clin Vaccine Immunol. 2006 Apr;13(4):511-9. doi: 10.1128/CVI.13.4.511-519.2006. Clin Vaccine Immunol. 2006. PMID: 16603621 Free PMC article.

10

Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides.

Viscidi RP, Hill PM, Li SJ, Cerny EH, Vlahov D, Farzadegan H, Halsey N, Kelen GD, Quinn TC. Viscidi RP, et al. J Acquir Immune Defic Syndr (1988). 1991;4(12):1190-8. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1941526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page